Scipher Medicine
Scipher Medicine is a precision immunology company combining network science and AI to develop molecular diagnostic tests and biomarker platforms for autoimmune diseases, serving rheumatologists, gastroenterologists, and pharmaceutical partners.
- Company typePrivate
- Founded2013
- HeadquartersWaltham, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Scipher Medicine does
Scipher Medicine is a precision immunology company that develops molecular diagnostic tests and AI-driven biomarker platforms for autoimmune diseases. The company's core technology is the Spectra AI Platform, which applies network science and proprietary AI algorithms to a human interactome map covering 89% of human cell proteins, enabling biomarker discovery and patient stratification for therapy selection. Its commercial diagnostic portfolio centers on the Prism franchise of laboratory-developed tests — PrismRA (commercially available blood-based test predicting TNFi non-response in rheumatoid arthritis, Medicare-covered since 2023), PrismUC (tissue-based test for ulcerative colitis), and research-phase tests PrismPSA (psoriatic arthritis) and PrismMS (multiple sclerosis) — backed by the PRoBeNet biomarker discovery framework and a data lake containing molecular samples from 30,000+ patients and clinical data on 300,000+ autoimmune patients.
Scipher serves two primary customer segments: healthcare providers (rheumatologists and gastroenterologists who order Prism tests to guide therapy selection and navigate step therapy), and pharmaceutical and biotech companies that license the platform's data, biomarkers, and AI capabilities for clinical trial design, patient stratification, and companion diagnostic co-development. Revenue is generated through diagnostic test billing to payers (including Medicare and commercial insurers), research collaborations, data licensing, and co-development agreements. The company has established strategic pharma partnerships with Galapagos, Ionis, Eli Lilly, Optum, Aitia, Savant Bio, Maxymune Therapeutics, Senelix, and a top-3 pharmaceutical company, and operates a distribution alliance with Grupo Amarey for Latin America.
Founded in 2013 by Drs. Joseph Loscalzo and Albert-László Barabási from research initiated in 2003, Scipher is headquartered in Waltham, Massachusetts, and is venture-backed through Series D with roughly $227 million disclosed in funding from Khosla Ventures, Northpond Ventures, United Health Group, Optum Ventures, Blue Owl, aMoon, Cowen, and other institutional investors. The company acquired CrossBridge in January 2023 to enhance real-time data capabilities and launched ClinicalTrialRank.com in August 2025 to extend its AI platform into clinical trial failure prediction for pharmaceutical R&D.
Scipher Medicine firmographics
Firmographics- Name
- Scipher Medicine
- Legal name
- Scipher Medicine Corporation
- Website
- https://sciphermedicine.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Scipher Medicine is a precision immunology company combining network science and AI to develop molecular diagnostic tests and biomarker platforms for autoimmune diseases, serving rheumatologists, gastroenterologists, and pharmaceutical partners.
- Ownership category
- akta.pro rank
Scipher Medicine industry classification
Industry- Product category
- Precision Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Real-World Evidence (RWE) & Outcomes Analytics for Precision Therapies (HLAAANAJ)
Keywords
Where Scipher Medicine is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Scipher Medicine business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Diagnostic Testing Services: Scipher generates revenue through laboratory-developed tests (LDTs) including PrismRA, PrismUC, and PrismPSA. These blood-based and tissue-based tests are prescribed by physicians and billed to payers (including Medicare) for predicting therapy response in autoimmune disease patients.
- Pharmaceutical Partnerships: Scipher partners with pharmaceutical companies for drug development, clinical trial design, patient stratification, and target discovery. Revenue comes from research collaborations, data licensing, and co-development agreements.
- Data Licensing and Insights: Scipher's extensive data lake (30K+ molecular samples, 300K+ patient clinical data) enables data licensing and insights services to pharmaceutical and biotech partners for drug discovery and development.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Scipher Medicine product offering
Product offeringCore offering
Scipher Medicine develops and commercializes laboratory-developed molecular signature response classifier tests (PrismRA, PrismUC) that predict patient response to biologic therapies in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. Its Spectra AI Platform combines a proprietary human interactome map with AI algorithms to power these diagnostic tests and enable biomarker discovery, patient stratification, and pharmaceutical drug development collaborations.
Product overview
Scipher Medicine offers a platform-plus-diagnostics portfolio centered on the Spectra AI Platform, which combines network science and AI to map autoimmune diseases at the molecular level. The platform enables biomarker discovery and patient stratification, powering a suite of Prism laboratory-developed diagnostic tests: PrismRA (commercially available for rheumatoid arthritis), PrismUC (in development for ulcerative colitis), PrismPsA (in research for psoriatic arthritis), and PrismMS (early research for multiple sclerosis). Supporting products include the PRoBeNet biomarker discovery framework and ClinicalTrialRank.com for clinical trial risk assessment. The Data Lake provides the foundational molecular and clinical data infrastructure across 300,000+ autoimmune patients.
Differentiator
Problem solved
Functional benefit
Brands
- PrismRA: Blood-based molecular signature response classifier test for rheumatoid arthritis that predicts TNFi non-response
- PrismUC
- PrismPSA
- PrismMS
- Spectra AI Platform
- PRoBeNet
- ClinicalTrialRank.com
Products and services
- PrismRA Blood-based molecular signature response classifier test that predicts inadequate response to TNF inhibitor (TNFi) therapies in rheumatoid arthritis patients, enabling personalized treatment selection from day one. Uses 23 biologic features including 19 gene transcripts, 1 serologic marker, and 3 clinical features.
- PrismUC Tissue-based molecular signature response classifier test being developed for ulcerative colitis patients to guide therapy decisions for those not reaching treatment goals through corticosteroids alone.
- PrismPsA Blood-based molecular signature response classifier test in research phase for psoriatic arthritis, designed to guide treatment selection and help patients get on the right medication for their biology sooner.
- PrismMS Early-stage research initiative for multiple sclerosis using the Spectra platform's database and network map to tackle the treatment pathway for MS.
- Spectra AI Platform AI-driven platform combining network science and machine learning to map autoimmune diseases at the molecular level, enabling patient stratification, biomarker discovery, target identification, and identification of appropriate treatment pathways for pharmaceutical and biotech partners.
- ClinicalTrialRank.com AI-driven platform that predicts clinical trial failure by analyzing drug targets and disease biology using network-based analysis to help de-risk investment decisions in drug development.
- PRoBeNet Predictive Response Biomarkers using Network medicine framework that discovers treatment-response-predicting biomarkers by analyzing protein-protein interaction networks and disease signatures, using the Personalized PageRank algorithm on the human interactome.
Quantifiable outcome
- 90% of RA patients who fail methotrexate are prescribed anti-TNF therapies, but most do not respond to treatment
- +6 more outcomes
Companies that use Scipher Medicine
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Scipher Medicine technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature7 records
Scipher Medicine partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core.
- GalapagoscoreCollaboration signed in 2020 focused on inflammatory bowel disease. Galapagos in-licensed novel drug targets from Scipher in 2022. Galapagos is a Belgian biopharmaceutical company.
- IoniscoreMulti-target partnership signed in 2023 with Ionis Pharmaceuticals, a leader in RNA-targeted therapeutics.
- Eli LillycorePartnership with Eli Lilly and Company for therapeutic development and commercialization.
- AitiacorePartnership with Aitia (formerly twoXAR) for biomarker discovery and validation using AI-driven approaches.
- OptumcorePartnership with Optum for healthcare data and analytics integration.
- SenelixcoreStrategic collaboration announced March 2026 to advance SL300 development (CHI3L1 antibody), focusing on precision medicine and co-developing a companion diagnostic using Scipher's AI-driven Spectra platform.
- Maxymune TherapeuticscoreStrategic collaboration announced September 2025 to accelerate target discovery in autoimmune and inflammatory diseases.
- Savant BiocoreExpanded strategic partnership announced July 2025 to build the world's most advanced clinico-genomic dataset in rheumatoid arthritis. Savant Bio is a Roivant-backed health data infrastructure company.
- Grupo AmareycoreStrategic alliance announced June 2025 to bring precision medicine to Latin America. Grupo Amarey is a leading company in representation and distribution of technologies, solutions, and services for the healthcare industry.
- Top-3 Pharmaceutical CompanycoreCollaboration announced June 2025 to integrate precision medicine into clinical trial design, integrating Scipher's PrismRA for therapy response segmentation.
- CrossBridgecoreAcquired in January 2023 to enhance capabilities in real-time data collection and patient treatment mapping for autoimmune diseases. CrossBridge is a data, analytics, and software company.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Scipher Medicine competitors and assessment
Company assessmentDirect peers
- Exagen: Exagen develops blood-based molecular diagnostic tests for autoimmune diseases such as lupus and rheumatoid arthritis. Directly comparable to Scipher's PrismRA as a precision immunology diagnostics company serving rheumatologists.
- Adaptive Biotechnologies: Adaptive Biotechnologies uses immune repertoire sequencing and AI for immune-mediated disease diagnostics and pharma partnerships (immune profiling, MRD). Comparable as a molecular immunology platform with pharma data monetization.
- Myriad Genetics: Myriad develops molecular diagnostic tests across multiple disease areas including autoimmune (Vectra DA for RA disease activity). Closely comparable as a specialty molecular diagnostics company with parallel pharma partnership channels.
- Veracyte: Veracyte is a genomic diagnostics company that develops molecular tests to resolve diagnostic ambiguity and inform treatment decisions. Comparable to Scipher's biomarker-driven precision diagnostics model.
- Caris Life Sciences: Caris offers AI-driven molecular profiling and precision medicine testing combined with a large clinico-genomic database for pharma partnerships. Directly comparable in business model (molecular diagnostics plus pharma data/biomarker services).
Broad incumbents
- Tempus Labs: Tempus is an AI-driven precision medicine company with broad molecular testing, a large clinical+molecular data library, and pharma data services. Overlapping with Scipher's Spectra platform but operating at a much larger scale.
- Exact Sciences: Exact Sciences is a leading molecular diagnostics company (Cologuard, Oncotype) with deep payer relationships, large clinical lab operations, and pharma services. A scaled incumbent with comparable molecular diagnostics capability.
- Foundation Medicine: Foundation Medicine provides comprehensive genomic profiling and pharma data services. Comparable as a molecular profiling + pharma partnership model, though oncology-focused and a subsidiary of Roche.
- Quest Diagnostics: Quest Diagnostics is one of the largest clinical reference laboratories offering autoimmune and specialty diagnostic testing with extensive payer coverage. Broad incumbent competing with Scipher's precision immunology tests.
- Laboratory Corporation of America (Labcorp): Labcorp is a leading global clinical laboratory network offering autoimmune and specialty diagnostics. Broad incumbent with extensive payer relationships that could distribute or compete with Scipher's precision tests.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Scipher Medicine social profiles
Digital presenceScipher Medicine compliance and trust
Trust signalCompliance1 record
Scipher Medicine financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scipher Medicine leadership team
Management profileNumber of profiles
Profiles11 records
Scipher Medicine subsidiaries and ownership
Company hierarchySubsidiaries1 record
Scipher Medicine funding detail
Funding detailFunding overview
Funding rounds6 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scipher Medicine M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scipher Medicine
What does Scipher Medicine do?
Scipher Medicine develops and commercializes laboratory-developed molecular signature response classifier tests (PrismRA, PrismUC) that predict patient response to biologic therapies in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. Its Spectra AI Platform combines a proprietary human interactome map with AI algorithms to power these diagnostic tests and enable biomarker discovery, patient stratification, and pharmaceutical drug development collaborations.
Is Scipher Medicine a public or private company?
Scipher Medicine is a private company. It is classified as venture growth investor backed and is currently operating.
When was Scipher Medicine founded?
Scipher Medicine was founded in 2013. It employs 51 to 100 people.
Where is Scipher Medicine based?
Scipher Medicine is headquartered in Waltham, United States, in the North America region.
How does Scipher Medicine make money?
Three revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are pharmaceutical Partnerships and data Licensing and Insights.
Who are Scipher Medicine's main competitors?
Direct peers on record are Exagen, Adaptive Biotechnologies, Myriad Genetics, Veracyte and Caris Life Sciences. Broad incumbents are Tempus Labs, Exact Sciences, Foundation Medicine, Quest Diagnostics and Laboratory Corporation of America (Labcorp).
Does Scipher Medicine have an API?
No public API is recorded for Scipher Medicine.
What industry is Scipher Medicine in?
Scipher Medicine's product category is Precision Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation). Its NAICS code is 62151 and its SIC code is 8071.